SA523441083B1 - أحماض بيرازولو بيبريدين كربوكسيليك تحمل بدائل - Google Patents
أحماض بيرازولو بيبريدين كربوكسيليك تحمل بدائلInfo
- Publication number
- SA523441083B1 SA523441083B1 SA523441083A SA523441083A SA523441083B1 SA 523441083 B1 SA523441083 B1 SA 523441083B1 SA 523441083 A SA523441083 A SA 523441083A SA 523441083 A SA523441083 A SA 523441083A SA 523441083 B1 SA523441083 B1 SA 523441083B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- diseases
- heart
- ejection fraction
- heart failure
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20213020 | 2020-12-10 | ||
| PCT/EP2021/084987 WO2022122914A1 (en) | 2020-12-10 | 2021-12-09 | Substituted pyrazolo piperidine carboxylic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA523441083B1 true SA523441083B1 (ar) | 2025-06-12 |
Family
ID=73793025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA523441083A SA523441083B1 (ar) | 2020-12-10 | 2023-06-07 | أحماض بيرازولو بيبريدين كربوكسيليك تحمل بدائل |
Country Status (30)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4011873A1 (en) * | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
| EP4011874A1 (en) * | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
| CN119300815A (zh) | 2022-06-09 | 2025-01-10 | 拜耳公司 | 用于治疗女性射血分数保留型心力衰竭的可溶性鸟苷酸环化酶激活剂 |
| JP2026504406A (ja) * | 2023-01-31 | 2026-02-05 | インビボサイエンシーズ インコーポレイテッド | 駆出率保持型心不全(HFpEF)の治療に関するシステムおよび方法 |
| AU2024348074A1 (en) * | 2023-09-27 | 2026-04-30 | Haisco Pharmaceutical Group Co., Ltd. | Pyrazole carboxylic acid derivative and use thereof in medicine |
| TW202535380A (zh) * | 2024-01-30 | 2025-09-16 | 大陸商海思科醫藥集團股份有限公司 | 吡唑羧酸衍生物及其在醫藥上的應用 |
| WO2026145681A1 (zh) * | 2025-01-03 | 2026-07-09 | 上海齐鲁制药研究中心有限公司 | 杂环羧酸类衍生物、其制备方法及其在医药上的应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| CN101939053A (zh) * | 2007-09-06 | 2011-01-05 | 默沙东公司 | 可溶性的鸟苷酸环化酶活化剂 |
| DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| ES2635340T3 (es) | 2010-02-27 | 2017-10-03 | Bayer Intellectual Property Gmbh | Ariltriazolonas ligadas a bis-arilo y su uso |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| EP2590979A1 (de) | 2010-07-09 | 2013-05-15 | Bayer Intellectual Property GmbH | Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| WO2012058132A1 (en) | 2010-10-28 | 2012-05-03 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
| MX338887B (es) * | 2012-09-07 | 2016-05-04 | Boehringer Ingelheim Int | Alcoxipirazoles como activadores de guanilato ciclasa soluble. |
| WO2015095515A1 (en) * | 2013-12-20 | 2015-06-25 | Novartis Ag | Sgc activators for the treatment of glaucoma |
| US20170313665A1 (en) | 2014-11-03 | 2017-11-02 | Bayer Pharma Aktiengesellschaft | Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof |
| GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
| CA3204595A1 (en) * | 2020-12-10 | 2022-06-16 | Bayer Aktiengesellschaft | Substituted pyrazolyl piperidine carboxylic acids |
| WO2022122917A1 (en) * | 2020-12-10 | 2022-06-16 | Bayer Aktiengesellschaft | The use of sgc activators for the treatment of ophthalmologic diseases |
-
2021
- 2021-12-09 CN CN202180081892.0A patent/CN116710439B/zh active Active
- 2021-12-09 SI SI202130234T patent/SI4259617T1/sl unknown
- 2021-12-09 CA CA3204495A patent/CA3204495A1/en active Pending
- 2021-12-09 GE GEAP202116287A patent/GEP20247649B/en unknown
- 2021-12-09 LT LTEPPCT/EP2021/084987T patent/LT4259617T/lt unknown
- 2021-12-09 WO PCT/EP2021/084987 patent/WO2022122914A1/en not_active Ceased
- 2021-12-09 US US18/256,647 patent/US20240051935A1/en active Pending
- 2021-12-09 RS RS20241357A patent/RS66294B1/sr unknown
- 2021-12-09 IL IL303296A patent/IL303296A/en unknown
- 2021-12-09 EP EP21823605.7A patent/EP4259617B1/en active Active
- 2021-12-09 HU HUE21823605A patent/HUE069255T2/hu unknown
- 2021-12-09 CR CR20230242A patent/CR20230242A/es unknown
- 2021-12-09 ES ES21823605T patent/ES2997117T3/es active Active
- 2021-12-09 HR HRP20241543TT patent/HRP20241543T1/hr unknown
- 2021-12-09 MX MX2023006903A patent/MX2023006903A/es unknown
- 2021-12-09 KR KR1020237022818A patent/KR20230118144A/ko active Pending
- 2021-12-09 AR ARP210103422A patent/AR124297A1/es unknown
- 2021-12-09 GE GEAP202316287A patent/GEAP202316287A/en unknown
- 2021-12-09 AU AU2021393988A patent/AU2021393988A1/en active Pending
- 2021-12-09 JP JP2023535063A patent/JP2023552583A/ja active Pending
- 2021-12-09 PE PE2023001808A patent/PE20231501A1/es unknown
- 2021-12-09 FI FIEP21823605.7T patent/FI4259617T3/fi active
- 2021-12-09 PT PT218236057T patent/PT4259617T/pt unknown
- 2021-12-09 DK DK21823605.7T patent/DK4259617T3/da active
- 2021-12-09 PL PL21823605.7T patent/PL4259617T3/pl unknown
-
2023
- 2023-06-01 EC ECSENADI202340828A patent/ECSP23040828A/es unknown
- 2023-06-02 CO CONC2023/0007335A patent/CO2023007335A2/es unknown
- 2023-06-06 CL CL2023001632A patent/CL2023001632A1/es unknown
- 2023-06-07 DO DO2023000115A patent/DOP2023000115A/es unknown
- 2023-06-07 SA SA523441083A patent/SA523441083B1/ar unknown
- 2023-06-08 JO JOJO/P/2023/0132A patent/JOP20230132A1/ar unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20230130A1 (ar) | أحماض بيرازولو بيبريدين كربوكسيليك تحمل بدائل | |
| JOP20230132A1 (ar) | أحماض بيرازولو بيبريدين كربوكسيليك تحمل بدائل | |
| Foti et al. | Acute kidney injury and extracorporeal membrane oxygenation: review on multiple organ support options | |
| MX357998B (es) | Una mezcla de acidos carboxilicos, especificamente acido citrico, acido succinico, acido fumarico y acido malico para el tratamiento de pacientes con insuficiencia renal cronica, insuficiencia renal aguda, hepatopatias agudas o cronicas que cursen con hiperamonemia, enfermedades congenitas con alteraciones enzimaticas en el ciclo de la urea, asi como condiciones clínicas que cursen con balance nitrogenado negativo. | |
| JOP20200098A1 (ar) | طرق علاج الفشل القلبي مع كسر قذفي منخفض بواسطة داباجليفلوزين | |
| JP2015120685A5 (cg-RX-API-DMAC7.html) | ||
| JP2016511238A5 (cg-RX-API-DMAC7.html) | ||
| Monardo et al. | Updates on hemodialysis techniques with a common denominator: The personalization of the dialytic therapy | |
| AR117640A1 (es) | Compuestos de 2,6-diaminopiridina como inhibidores de khk | |
| Schaefer et al. | Bleeding and thrombotic events in post-cardiotomy extracorporeal life support | |
| Unarokov et al. | Comparison of sustained low‐efficiency dialysis with acetate‐free and acetate‐containing bicarbonate dialysate in unstable patients | |
| CN103074319B (zh) | 一种尿激酶与人尿胰蛋白酶抑制剂的分离方法 | |
| DOP2017000141A (es) | Ácido 3-(6-alcoxi-5-clorobenzo[d]isoxazol-3-il)propanoico útil como inhibidores de quinurenina monooxigenasa | |
| Canaud et al. | Whole‐blood viscosity increases significantly in small arteries and capillaries in hemodiafiltration. Does acute hemorheological change trigger cardiovascular risk events in hemodialysis patient? | |
| Khilnani | Anticoagulation on extracorporeal membrane oxygenation (ECMO) | |
| Epstein et al. | A Comparison of the Efficacy of Patiromer Plus RAAS Inhibitor Therapy in Patients with CKD and Diabetes to a Cohort of Patients Not Using Patiromer: A Real-World Analysis Using Propensity Score Matching: PO2369 | |
| Figurek et al. | What is the place of sclerostin in chronic kidney disease, atherosclerosis, and ageing? | |
| MX364490B (es) | Composición farmacéutica para el mejoramiento de la condición general de enfermos crónicos con estados de pérdida de energía y proteínas. | |
| Ghatak | Methanol toxicity: case report | |
| Subbotina et al. | Experience with Initial Full Coagulation Regime after Neonatal Postcardiotomy Extracorporeal Membrane Oxygenation (ECMO) | |
| CN104586884A (zh) | 新型血液透析浓缩液 | |
| CN105560697A (zh) | 用于治疗高血压的雪羹汤 | |
| CN105558598A (zh) | 用于治疗高血压的双耳汤 | |
| RU2007145065A (ru) | Способ выделения надмолекулярно-генетических структур из грамотрицательных клеток прокариот |